GSK

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Peers: AZN SNY NVS MRK PFE ABBV BMY JNJ LLY NVO

| Held by: AVDE FENI PPH FVD AVIV DFAX RODM GMOI AQEC TOUS

Index	-
Market Cap	105.82B
Enterprise Value	125.85B
Income	7.83B
Sales	43.93B
Book/sh	11.71
Cash/sh	2.27
Dividend Est.	1.87 (3.53%)
Dividend TTM	1.80 (3.41%)
Dividend Ex-Date	May 15, 2026
Dividend Gr. 3/5Y	8.77% -7.68%
Payout	46.93%
Employees	66841
IPO	Mar 28, 1980

P/E	13.81
Forward P/E	10.12
PEG	1.91
P/S	2.41
P/B	4.51
P/C	23.31
P/FCF	13.39
EV/EBITDA	8.39
EV/Sales	2.86
Quick Ratio	0.52
Current Ratio	0.79
Debt/Eq	1.07
LT Debt/Eq	0.78
Option/Short	Yes / Yes

EPS (ttm)	3.82
EPS next Y	5.22
EPS next Q	1.23
EPS this Y	1.28%
EPS next Y	9.57%
EPS next 5Y	5.31%
EPS past 3/5Y	-25.93% 0.08%
Sales past 3/5Y	6.03% -0.31%
EPS Y/Y TTM	98.98%
Sales Y/Y TTM	9.19%
EPS Q/Q	16.20%
Sales Q/Q	8.60%
Earnings	Apr 29 BMO
EPS/Sales Surpr.	8.75% 0.69%

Insider Own	0.01%
Insider Trans	0.00%
Inst Own	18.81%
Inst Trans	-12.61%
ROA	9.71%
ROE	37.44%
ROIC	18.63%
Gross Margin	72.81%
Oper. Margin	24.55%
Profit Margin	17.82%
SMA20	2.73%
SMA50	1.77%
SMA200	4.72%
Trades

Shs Outstand	2.01B
Shs Float	2.00B
Short Float	0.42%
Short Ratio	2.12
Short Interest	8.40M
52W High	61.69 -14.40%
52W Low	35.45 48.97%
Volatility	1.74% 1.67%
ATR (14)	1.06
RSI (14)	56.44
Beta	0.36
Rel Volume	1.06
Avg Volume	3.96M
Volume	4,183,345

Perf Week	4.08%
Perf Month	3.06%
Perf Quarter	-1.91%
Perf Half Y	7.86%
Perf YTD	7.69%
Perf Year	36.88%
Perf 3Y	49.10%
Perf 5Y	29.85%
Perf 10Y	22.18%
Recom	2.43
Target Price	57.73
Prev Close	52.50
Price	52.81
Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Initiated	Citigroup	Neutral
Jan-06-26	Downgrade	Barclays	Equal Weight → Underweight
Nov-25-25	Upgrade	BofA Securities	Underperform → Neutral
Jun-03-25	Downgrade	Berenberg	Buy → Hold
Apr-15-25	Initiated	Exane BNP Paribas	Neutral	$35.25
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Nov-15-24	Downgrade	Deutsche Bank	Buy → Hold
Nov-12-24	Downgrade	Jefferies	Buy → Hold	$53 → $39.50
Oct-31-24	Downgrade	Guggenheim	Buy → Neutral
Jul-08-24	Downgrade	UBS	Buy → Neutral
May-30-24	Initiated	Goldman	Neutral	$47
Mar-04-24	Upgrade	Guggenheim	Neutral → Buy
Feb-13-24	Upgrade	Citigroup	Neutral → Buy
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$44
Jan-16-24	Resumed	UBS	Buy
Jan-03-24	Upgrade	Jefferies	Hold → Buy	$48
Jul-14-23	Initiated	HSBC Securities	Reduce
Mar-17-23	Upgrade	Deutsche Bank	Hold → Buy
Feb-27-23	Resumed	Goldman	Buy
Jan-03-23	Downgrade	JP Morgan	Neutral → Underweight

Show Previous Ratings

Jun-17-26 04:21PM	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) (Business Wire)
Jun-11-26 03:56PM	Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates (Exec Edge)
Jun-10-26 09:42AM	Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls (The Fly)
08:21AM	GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts (Proactive)
Jun-09-26 04:03PM	GSK Bets Big on Cancer With Nuvalent Deal (GuruFocus.com)
11:29AM	Loading…
11:29AM	GSK Just Dropped $10.6 Billion on a Lung Cancer Bet (Moby)
10:10AM	GSK Buys Nuvalent for $10.6 Billion in Major Cancer Push (Bloomberg)
09:20AM	GSK Agrees $10.6 Billion Nuvalent Deal at 40% Premium (GuruFocus.com)
08:16AM	Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal (Barrons.com)
06:06AM	NUVL Stock Surges 39% Premarket Why Is GSK Buying This Boston-Based Oncology Company? (Stocktwits)
05:56AM	Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move. (Barrons.com)
03:37AM	GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down (MarketWatch)
02:25AM	GSK falls as £8bn takeover of Nuvalent is largest deal in a decade (Proactive)
02:25AM	GSK falls after agreeing £8bn Nuvalent takeover to bolster oncology pipeline (Proactive)
02:25AM	GSK agrees £8bn Nuvalent takeover to bolster oncology pipeline (Proactive)
07:57AM	Loading…
Jun-04-26 07:57AM	US bank sees GSK oncology pipeline as major value driver after New York conference (Proactive)
Jun-03-26 07:54AM	UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags (Proactive)
03:15AM	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors (TMX Newsfile)
May-29-26 09:30AM	GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading (Proactive)
May-28-26 06:22PM	GSK Drug Shows 19%-20% Hepatitis B Cure Rate In Late-Stage Trials (GuruFocus.com)
May-18-26 02:22PM	B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire)
May-12-26 06:23AM	GSK and SBP Group team up to advance bepirovirsen launch in China (Pharmaceutical Business Review)
Apr-30-26 09:32AM	JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited (Proactive)
03:05AM	GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion (GuruFocus.com)
Apr-29-26 06:09AM	American industry is winning: White House touts factory boom how investors can ride the reshoring wave (Moneywise) -5.64%
02:42AM	Glaxo: Q1 Earnings Snapshot (Associated Press)
02:35AM	GSK Q1 Core Profit Rises; Affirms 2026 Guidance (RTT News)
02:19AM	GSK reaffirms 2026 guidance after strong first-quarter performance (Proactive)
Apr-27-26 02:58AM	GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio (Proactive)
Apr-13-26 12:48PM	GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% (GuruFocus.com)
10:44AM	Loading…
Mar-30-26 10:44AM	Pharma Stocks Pfizer, GSK Offer Defensive Plays in an Uncertain Market: Charts (Barrons.com)
Mar-25-26 10:15AM	Broker reiterates GSK 'buy' as court ruling lifts vaccine cloud (Proactive)
Mar-13-26 11:44AM	GSKs RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 1849 Years at Increased Risk (Business Wire)
Mar-11-26 06:32AM	FDA approves GSK's Wellcovorin for cerebral folate deficiency (Pharmaceutical Business Review)
Mar-10-26 01:59PM	FDA Expands Use Of Generic Drug To Treat Autism-Linked Genetic Disorder (Benzinga)
11:38AM	GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma (Zacks)
11:31AM	JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer (Zacks)
Mar-09-26 05:05PM	Top Stock Reports for Visa, Chevron & Toyota Motor (Zacks)
04:12AM	GSK sells rights to rare liver disease drug for up to $690m (Proactive)
03:39AM	GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million (The Wall Street Journal)
Mar-08-26 06:58PM	Is It Too Late to Buy GSK After a 46% Share Price Jump? (24/7 Wall St.)
04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
Mar-02-26 07:49AM	MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot (Zacks)
Feb-26-26 09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
Feb-25-26 07:22AM	GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play (Benzinga)
02:27AM	GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments (Proactive)
Feb-24-26 11:43AM	GSK Strikes $1 Billion China RNA Deal (GuruFocus.com)
11:31AM	SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus (Zacks)
02:11AM	GSK (GSK) Announces 75.6% Vaccine Effectiveness for Arexvy in Real-World RSV Study (Insider Monkey)
Feb-23-26 01:13PM	Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract (Business Wire)
Feb-19-26 11:31AM	Europe Clears GSK's New Twice-Yearly Asthma Treatment (Benzinga)
10:30AM	Moderna Stock Jumps After FDA Reverses Course on Flu Shot (Zacks)
07:56AM	Merck Discloses Positive Data For Respiratory Syncytial Virus Antibody Treatment, Seeks FDA Nod For Broader Child Use (Benzinga)
Feb-18-26 08:00AM	GSKs AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows (Business Wire)
Feb-17-26 06:31AM	Europe Clears GSK's New Twice-Yearly Asthma Treatment (Benzinga)
Feb-15-26 09:10AM	GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17% (Insider Monkey)
Feb-13-26 10:59AM	Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms (Benzinga)
09:36AM	Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026? (Zacks)
Feb-11-26 10:15AM	GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales (Zacks)
Feb-09-26 07:15AM	Citi lifts GSK target price but keeps neutral stance after rally (Proactive)
Feb-06-26 11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
05:15AM	ShoreCap says GSK has cracked it and the £40bn prize is now in sight (Proactive)
Feb-05-26 09:15AM	Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings? (Zacks)
02:04AM	Analyst Report: GSK plc (Morningstar Research)
Feb-04-26 09:00PM	Analyst Report: GSK plc (Morningstar Research) +7.29%
04:05PM	GSK Is Eyeing $55 Billion In Sales And It Has Nothing To Do With Obesity (Investor's Business Daily)
01:52PM	GSK Shares Jump 5.2% as New CEO Signals Faster R&D, Deal Push (GuruFocus.com)
01:50PM	GSK Beats Estimates, Sticks With Long-Term Outlook (GuruFocus.com)
12:01PM	GSK PLC (GSK) Q4 2025 Earnings Call Highlights: Strong Financial Performance and Strategic ... (GuruFocus.com)
10:30AM	GSK beat the numbers, but the real story was the guidance (Proactive)
08:31AM	GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook (Zacks)
08:12AM	GSK Stock Smashes 52-Week High On Strong Quarter, Dividend Hike (Benzinga)
07:27AM	GSK Q4 Earnings Call Highlights (MarketBeat)
07:05AM	GSK (GSK) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
02:45AM	GSKs Specialty Medicines Drive Solid Results (The Wall Street Journal)
02:20AM	Glaxo: Q4 Earnings Snapshot (Associated Press Finance)
Feb-03-26 12:30PM	Wave Life Sciences price target raised to $50 from $47 at Clear Street (TipRanks)
09:40AM	Why GSK (GSK) is a Top Value Stock for the Long-Term (Zacks)
07:17AM	GSK PLC (LSE:GSK) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Feb-02-26 02:16PM	Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path (Benzinga)
10:01AM	AstraZeneca Shares Start Trading in US After Listing Upgrade (Bloomberg)
08:29AM	Palantir, AMD, Amazon and More Stocks with Earnings This Week (Benzinga)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-29-26 10:00AM	Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-28-26 10:00AM	GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:45AM	Here's Why GSK (GSK) is a Strong Growth Stock (Zacks)
05:51AM	Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle (Benzinga)
Jan-27-26 09:50AM	Here's Why GSK (GSK) is a Strong Momentum Stock (Zacks)
Jan-22-26 01:03AM	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality (Reuters)
Jan-21-26 10:23AM	GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout (Zacks)
10:00AM	GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026 (Business Wire)
Jan-20-26 05:30PM	Why Rapt Therapeutics Stock Soared Today (Motley Fool)
04:05PM	GSK Digs In On Allergies With $2.2 Billion Rapt Therapeutics Buyout (Investor's Business Daily)
01:41PM	BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? (Zacks)
09:36AM	Stocks to Watch Tuesday: 3M, Nvidia, Netflix, Warner Bros. (The Wall Street Journal)
09:00AM	GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million (Business Wire)
07:10AM	This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. (Barrons.com)
05:54AM	GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough (Benzinga)
Jan-15-26 09:40AM	Here's Why GSK (GSK) is a Strong Value Stock (Zacks)
08:53AM	Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? (Zacks)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

CFO & Executive DirectorMs. Julie Belita Brown A.C.A.

Executive OfficerMs. Emma Natasha Walmsley

M.P.H.Dr. Jesse L. Goodman M.D.

CEO & DirectorMr. Luke Victor Miels

Chief Digital & Technology OfficerMs. Shobie Ramakrishnan

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GSK plc	10% Owner	Dec 11 '25	Buy	19.00	1,470,000	27,930,000	18,245,691	Dec 15 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

GSK Plc ADR

Upgrade your Finviz experience